Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group.

Autor: Bradshaw D; National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK. Electronic address: daniel.bradshaw@phe.gov.uk., Mbisa JL; National Infection Service, Public Health England, London, UK., Geretti AM; Institute of Infection and Global Health, University of Liverpool, UK., Healy BJ; Public Health Wales, Cardiff, UK., Cooke GS; Imperial College London, London, UK., Foster GR; Queen Mary University of London, London, UK., Thomson EC; MRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland, UK., McLauchlan J; MRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland, UK., Agarwal K; Institute of Liver Studies, King's College Hospital, London, UK., Sabin C; University College London, London, UK., Mutimer D; University of Birmingham, Birmingham, UK., Moss P; Hull University Teaching Hospitals NHS Trust, UK., Irving WL; Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham, UK., Barnes E; Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.
Jazyk: angličtina
Zdroj: The Journal of infection [J Infect] 2019 Dec; Vol. 79 (6), pp. 503-512. Date of Electronic Publication: 2019 Oct 16.
DOI: 10.1016/j.jinf.2019.10.007
Abstrakt: The treatment of hepatitis C virus (HCV) infection has been revolutionised by the advent of oral, well-tolerated, direct acting antiviral therapies (DAA), with high cure rates. However, in some scenarios, HCV resistance to antiviral therapies may have an impact on treatment success. Public Health England's HCV Resistance Group was established to support clinicians treating people with HCV, where the issue of resistance may be a factor in clinical decision-making, and this review includes the Group's current recommendations on the use of HCV resistance testing. The authors describe the principles behind and approach to HCV resistance testing and consider evidence from in vitro studies, clinical trials and real world cohorts on the impact of HCV resistance on treatment outcomes for particular DAA regimens. Five scenarios are identified in the UK and similar settings, where, in the Group's opinion, resistance testing should be performed.
(Crown Copyright © 2019. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: